139 related articles for article (PubMed ID: 18523732)
21. [New trends in functional medical imaging: quantitative methods].
Balkay L; Emri M; Galuska L; Garai I; Kis AS; Szûcs B; Varga J
Magy Onkol; 2014 Dec; 58(4):251-60. PubMed ID: 25517443
[TBL] [Abstract][Full Text] [Related]
22. Molecular imaging of tumor metabolism and apoptosis.
Haberkorn U; Markert A; Mier W; Askoxylakis V; Altmann A
Oncogene; 2011 Oct; 30(40):4141-51. PubMed ID: 21577202
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
24. Cancer drug development using glucose metabolism radiopharmaceuticals.
Sun YY; Chen Y
Curr Pharm Des; 2009; 15(9):983-7. PubMed ID: 19275662
[TBL] [Abstract][Full Text] [Related]
25. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond.
Mankoff DA; Bellon JR
Semin Radiat Oncol; 2001 Jan; 11(1):16-27. PubMed ID: 11146039
[TBL] [Abstract][Full Text] [Related]
26. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
[TBL] [Abstract][Full Text] [Related]
27. Post-carotid endarterectomy changes in cerebral glucose metabolism on (18)F-fluorodeoxyglucose positron emission tomography associated with postoperative improvement or impairment in cognitive function.
Yoshida K; Ogasawara K; Saura H; Saito H; Kobayashi M; Yoshida K; Terasaki K; Fujiwara S; Ogawa A
J Neurosurg; 2015 Dec; 123(6):1546-54. PubMed ID: 26230467
[TBL] [Abstract][Full Text] [Related]
28. Using PET/CT imaging to characterize 18 F-fluorodeoxyglucose utilization in fish.
Browning ZS; Wilkes AA; Mackenzie DS; Patterson RM; Lenox MW
J Fish Dis; 2013 Nov; 36(11):911-9. PubMed ID: 23488673
[TBL] [Abstract][Full Text] [Related]
29. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
30. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
31. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
32. Use of positron emission tomography in oncology.
Glaspy JA; Hawkins R; Hoh CK; Phelps ME
Oncology (Williston Park); 1993 Jul; 7(7):41-6, 49-50; discussion 50-2, 55. PubMed ID: 8347460
[TBL] [Abstract][Full Text] [Related]
33. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
34. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
35. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
[TBL] [Abstract][Full Text] [Related]
36. Molecular imaging of tumor metabolism and apoptosis.
Haberkorn U; Altmann A; Mier W; Eisenhut M
Ernst Schering Found Symp Proc; 2007; (4):125-52. PubMed ID: 18811056
[TBL] [Abstract][Full Text] [Related]
37. Imaging pulmonary inflammation with positron emission tomography: a biomarker for drug development.
Chen DL; Schuster DP
Mol Pharm; 2006; 3(5):488-95. PubMed ID: 17009847
[TBL] [Abstract][Full Text] [Related]
38. Why glucose transport in the brain matters for PET.
Barros LF; Porras OH; Bittner CX
Trends Neurosci; 2005 Mar; 28(3):117-9. PubMed ID: 15749163
[TBL] [Abstract][Full Text] [Related]
39. New aspects of the Warburg effect in cancer cell biology.
Bensinger SJ; Christofk HR
Semin Cell Dev Biol; 2012 Jun; 23(4):352-61. PubMed ID: 22406683
[TBL] [Abstract][Full Text] [Related]
40. Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies.
Pantel AR; Ackerman D; Lee SC; Mankoff DA; Gade TP
J Nucl Med; 2018 Sep; 59(9):1340-1349. PubMed ID: 30042161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
